Study Overview: This is a research study to test a new drug called CPI-0209 in people with advanced cancer or lymphoma. CPI-0209 is a special type of medicine that blocks a protein called EZH2 which is sometimes found in high amounts in cancer cells. The study has two parts (Phase 1 and Phase 2) to see if the drug is safe and how well it works.
Phase 1: This part is to find the best dose of CPI-0209 that can be given safely. People who join this part have cancers that didn't respond to regular treatments.
Phase 2: This part will test the drug in specific types of cancer in different groups of patients to see how well it works and how safe it is. There will be multiple groups (cohorts) with different types of cancers.
- Study Duration: The study involves multiple phases, possibly lasting several months.
- Who Can Join: Adults with advanced cancer or lymphoma, after other treatments didn't work.
- Compensation: Participants may receive compensation for their time and travel.
How understandable was the trial content above?
Hard to understand
Easy to understand